Appraisal of effectiveness and potential therapeutic benefit of acarbose: A non-consensus conference

Diabetologia

Volumn 39, Issue 7, 1996, Pages 873-874

  Berger, M ^a   Kobberling J ^b   Windeler, J ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; SULFONYLUREA DERIVATIVE;

CONFERENCE PAPER; DIABETES MELLITUS; HUMAN; PRIORITY JOURNAL; THERAPY;

EID: 0030013538     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03035774     Document Type: Conference Paper

References (5)

1. Alberti KGMM, Gries FA, Jervell J, Krans HJM for the European NIDDM Policy Group (1994) A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabet Med 11: 899-909
2. Schatz H for the German Diabetes Association (1995) Zur klinischen Wirksamkeit und Zweckmäßigkeit von Acarbose und Metformin in der Therapie des Diabetes mellitus. Diabetes und Stoffwechsel 4: 407-421
3. Schwabe U, Paffrath D (1995) Arzneiverordnungs-Report, Gustav-Fischer, Stuttgart-Jena
4. Sackett DL, Rosenberg WMC, Gray JAM et al. (1996) Evidence based medicine: what it is and what it isn't. BMJ 312: 71-72
5. Turner R, Cull C, Holman R for the United Kingdom Prospective Diabetes Study Group (1996) United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124 [1 pt. 2]: 136-145